Mostrando 10 resultados de: 44
Filtros aplicados
Publisher
Pharmacogenomics(7)
European Journal of Clinical Pharmacology(6)
Drug Metabolism and Drug Interactions(5)
Pharmacogenomics Journal(4)
Current Drug Targets(2)
Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
ReviewAbstract: CYP2D6 is described as the most relevant enzyme in the metabolism of many antipsychotic drugs. Its cPalabras claves:Antipsychotic drugs, CYP2D6, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Berecz R., Cáceres M.C., Dorado P., Penãs-Lledó E.M.Fuentes:scopusAnalysis of diclofenac and its metabolites by high-performance liquid chromatography: Relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios
ArticleAbstract: In humans, diclofenac is metabolised to 4′-hydroxy (OH), 3′-OH and 5-OH metabolites. The polymorphicPalabras claves:CYP2C9 genotypes, Diclofenac, HydroxydiclofenacAutores:Adrián LLerena, Berecz R., Cáceres M.C., Dorado P.Fuentes:scopusAntipsychotic drugs and QTc prolongation: The potential role of CYP2D6 genetic polymorphism
ReviewAbstract: Although the most common, and usually serious, side effects of first-generation (or typical) antipsyPalabras claves:Antipsychotic drugs, Cardiac side effects, CYP2D6, drug metabolism, QT interval lengthening, Torsades de pointes-type arrhythmiaAutores:Adrián LLerena, Berecz R., Dorado P., Penãs-Lledó E.M.Fuentes:scopusDetermination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: Application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship
ArticleAbstract: The drug-metabolizing cytochrome P450 (CYP) enzyme CYP2D6 is involved in the metabolism of several cPalabras claves:CYP2D6, debrisoquine, HPLC, Metabolic ratioAutores:Adrián LLerena, Berecz R., Cáceres M.C., Cobaleda J., Dorado P., González I.Fuentes:scopusDetermination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients
ArticleAbstract: A rapid high-performance liquid chromatographic method is described for the simultaneous determinatiPalabras claves:Fluoxetine, NorfluoxetineAutores:Adrián LLerena, Berecz R., Cáceres M.C., De la Rubia A., Dorado P., González A.P., Jesus Norberto M.Fuentes:scopusDevelopment of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes
ArticleAbstract: Background: Losartan is metabolized to losartan carboxylic acid (E-3174) by the polymorphic cytochroPalabras claves:CYP2C9*Hispanics, LOSARTÁN, pharmacogenetics, PhenotypeAutores:Adrián LLerena, de Andrés F., Dorado P., Machín E., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusCYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
ArticleAbstract: Objective: This study analyzed the frequency of CYP2C9 variant alleles and evaluated the impact of CPalabras claves:CYP2C9, Diclofenac, GenotypingAutores:Adrián LLerena, Berecz R., Dahl M.L., Dorado P., Norberto M., Yasar U.Fuentes:scopusCYP2D6 ethnic variability in hispanics
Book PartAbstract: Genetic polymorphism in the CYP2D6 gene results in a wide variability in CYP2D6 enzymatic activity,Palabras claves:Autores:Adrián LLerena, Dorado P., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population
ArticleAbstract: Purpose: Cytochrome P450 2D6 (CYP2D6) genotypes and the dextromethorphan/dextrorphan (DXM/DXT) metabPalabras claves:CYP2D6, dextromethorphan, ECUADOR, pharmacogeneticsAutores:Adrián LLerena, Dorado P., Enrique Terán, Francisco J.López Hernández, Machín E., Natalia HerasFuentes:scopusCYP2D6 polymorphism: Implications for antipsychotic drug response, schizophrenia and personality traits
ReviewAbstract: The CYP2D6 gene is highly polymorphic, causing absent (poor metabolizers), decreased, normal or incrPalabras claves:Adverse side effects, antipsychotics, CYP2D6, personality, pharmacogenetics, Pharmacogenomics, QTc, Schizophrenia, vulnerabilityAutores:Adrián LLerena, Dorado P., Penãs-Lledó E.M.Fuentes:scopus